New Funding Infrastructure

New Funding Infrastructure for a Changing Research Economy

BioCrowd is an institutional research funding platform that helps hospitals, universities, and patient communities raise milestone-based capital when traditional grants fall short.

As federal funding becomes less predictable, institutions need new, compliant capital sources. BioCrowd provides clinical research funding infrastructure that unlocks Donor-Advised Funds, venture philanthropy, and impact investing in biotech.

A Growing Clinical Research Funding Crisis

NIH funding uncertainty is creating a widening capital gap across clinical and translational research. Institutions are experiencing:

Delayed or Cancelled Clinical Trials

Funding shortfalls are forcing institutions to pause or abandon promising research programs.

Fewer Early-Stage Translational Programs

Promising proof-of-concept work is stalling before it can attract industry funding.

Increasing Reliance on Alternative Funding

Institutions are scrambling to find new capital sources without the right infrastructure.

BioCrowd was built to address this clinical research funding crisis.

By connecting institutions with new capital sources — donor-advised funds, venture philanthropy, and impact-aligned investors — BioCrowd provides the infrastructure research organizations need to keep moving forward.

See How It Works

The BioCrowd Capital Layer

BioCrowd is the capital-raising layer that sits between advancement, tech transfer, and research administration systems.

Alternative Capital Source (alongside NIH & foundation grants) Specialized Platform for Translational Research R1 & R2 University & Hospital Research Funding SaaS Purpose-Built Capital Marketplace for Research-Driven Spinouts Venture Philanthropy Platform for Biotech Capital Layer Feeding Trials Managed in CTMS Financial Rails Tied to Milestone Data Funding Marketplace for the Tech Transfer Pipeline External Funding Layer Fed into ERP Systems Capital Aligned to Datasets & Patient Cohorts Funding Released Only After IRB-Approved Milestones

Capital Flow

Source
Advancement
Source
Tech Transfer
BioCrowd
Capital Layer
Destination
CTMS / ERP

Milestone-Based Capital for Institution-Approved Research

BioCrowd helps hospitals, universities, and research institutes raise capital aligned to scientific and regulatory milestones.

01

Institution Approval

Projects are submitted and approved by universities, hospitals, or research institutes and defined with specific scientific, clinical, and regulatory milestones.

02

Campaign Design

BioCrowd structures milestone-based funding tranches, legal frameworks, reporting models, and donor/investor participation structures.

03

Funding

Donors, foundations, and investors fund institution-approved campaigns. Capital is released only when milestones are achieved.

04

Progress & Reporting

Institutions provide milestone-based updates on scientific progress, data readouts, regulatory steps, and licensing or partnership discussions.

Learn More About How It Works

Built for Institutions & Funders

Research Institutions

Accelerate your research funding with our innovation platform designed specifically for academic research institutions and hospital health systems.

  • Raise Capital from Untapped Donor Segments
    Discover new tools and channels for capital investment.
  • Project Management
    Streamlined submission and tracking of research projects.
  • Milestone Tracking
    Real-time progress monitoring with blockchain verification.
  • Team Collaboration
    Collaborative workspace for research teams and stakeholders.
  • Compliance Management
    Built-in regulatory compliance and reporting tools.
  • Funding Analytics
    Comprehensive insights into funding performance and trends.
  • Global Network
    Access to international funding opportunities and partnerships.

BioCrowd is designed specifically for academic medical centers, R1 and R2 university research programs, and hospital-based research organizations seeking compliant, transparent alternatives to traditional NIH grant funding.

Launch a Research Campaign →

Donors & Investors

Discover high-impact biomedical research opportunities and track your investments with unprecedented transparency and control.

  • Project Discovery
    AI-powered matching with high-potential research projects.
  • Portfolio Dashboard
    Comprehensive view of all investments and performance metrics.
  • Real-Time Updates
    Instant notifications on project milestones and progress.
  • Risk Assessment
    Advanced analytics for investment risk evaluation.
  • Impact Measurement
    Track the social and scientific impact of your investments.
  • Secure Transactions
    Bank-grade security with blockchain transparency.

Accredited investors may elect to receive alerts regarding institution-supported investment opportunities, including SAFE Note–based or SPV structures linked to research programs. Or donate for a tax deduction and self-direct your contribution to the lab, disease, researcher, or institution of your choice.

Fund a Clinical Breakthrough →

Capital Sources BioCrowd Unlocks

BioCrowd helps institutions raise capital from multiple compliant channels.

Donor-Advised Fund Capital

Tax-efficient philanthropic giving through established DAF sponsors.

Venture Philanthropy Funding

Mission-aligned capital from foundations and philanthropic investors.

Impact Investor Capital

Returns-seeking capital aligned to scientific and social milestones.

Compliant Biotech SAFE Investments

Early-stage equity structures linked to translational research spinouts.

BioCrowd Connects the Full Research-to-Return Chain

Institution-Led Research
Milestone Funding
Defensible IP
Licensing or Acquisition
Investor Returns

BioCrowd Featured Projects

Institution-approved research programs seeking milestone-based capital.

Cancer
$1.25M USD
AI-Enabled Therapeutic Antibody Discovery Against Age-Related Cancer Types. 1 Antibody Against 4 Age-Related Cancer Types.
Neurology
$500,000
Research on Neuropsychiatric Disorder
Immunology
$370,000
Active Immunotherapy for Acute Lymphoblastic Leukemia
Rare Diseases
$850,000
Research on Nephropathic Cystinosis
Longevity
$550,000
The Real Science Behind the Billionaire Pursuit of Immortality
Cancer
$900,000
Developing a New Type of Treatment for Leukaemia